1676 documents

Read All
00:20 , Jun 11, 2019 |  BC Extra  |  Clinical News

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

Novo’s oral semaglutide meets in Phase III trials  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported results from two Phase III trials of its oral semaglutide in Type II diabetes. In PIONEER 2, oral semaglutide, a...
Read More
23:45 , May 16, 2019 |  BC Innovations  |  Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
Read More
22:52 , May 3, 2019 |  BC Extra  |  Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
Read More
22:52 , Apr 26, 2019 |  BC Extra  |  Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
Read More
18:36 , Apr 26, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
Read More
22:44 , Apr 25, 2019 |  BC Extra  |  Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
Read More
18:52 , Apr 17, 2019 |  BC Extra  |  Politics & Policy

Cummings defends drug price information request

House Energy & Commerce Committee Chairman Elijah Cummings (D-Md.) Wednesday denounced Jim Jordan (R-Ohio) for attempting to thwart the committee’s investigation into prescription drug prices. Cummings was responding to a letter Jordan sent on April...
Read More
12:21 , Apr 16, 2019 |  BC Extra  |  Company News

With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover...
Read More
19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
Read More
19:50 , Apr 10, 2019 |  BC Extra  |  Politics & Policy

Insulin manufacturers, PBMs spar over rebates and pricing

Insulin manufacturers and PBMs sparred at a congressional hearing Wednesday, blaming each other for escalating list prices of diabetes drugs and offering opposing policy prescriptions. The three companies that manufacture almost all of the insulin...
Read More